AR and prostate cancer: They also have different androgen sensitivity and AR status, which is an important implication that blocking DHT production with either 5α-reductase inhibitor may not be the gold-standard prevention strategy in every man because the androgen sensitivity, AR status and other factors of each particular prostate cancer may influence expression of 5α-reductase isoenzymes in reponses to blocking of DHT production.